These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

611 related items for PubMed ID: 23438937

  • 1. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.
    Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A.
    Health Technol Assess; 2013 Feb; 17(7):1-166. PubMed ID: 23438937
    [Abstract] [Full Text] [Related]

  • 2. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
    Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A.
    Lancet; 2011 Jul 30; 378(9789):403-11. PubMed ID: 21764118
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
    Banerjee S, Farina N, Henderson C, High J, Stirling S, Shepstone L, Fountain J, Ballard C, Bentham P, Burns A, Fox C, Francis P, Howard R, Knapp M, Leroi I, Livingston G, Nilforooshan R, Nurock S, O'Brien J, Price A, Thomas AJ, Swart AM, Telling T, Tabet N.
    Health Technol Assess; 2023 Oct 30; 27(23):1-108. PubMed ID: 37929672
    [Abstract] [Full Text] [Related]

  • 5. Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial.
    Zuidersma M, Chua KC, Hellier J, Voshaar RO, Banerjee S, HTA-SADD Investigator Group.
    Am J Geriatr Psychiatry; 2019 Sep 30; 27(9):920-931. PubMed ID: 31084994
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial.
    Duffy L, Bacon F, Clarke CS, Donkor Y, Freemantle N, Gilbody S, Hunter R, Kendrick T, Kessler D, King M, Lanham P, Lewis G, Mangin D, Marston L, Moore M, Nazareth I, Wiles N, Lewis G.
    Trials; 2019 Jun 03; 20(1):319. PubMed ID: 31159856
    [Abstract] [Full Text] [Related]

  • 8.
    Duffy L, Lewis G, Ades A, Araya R, Bone J, Brabyn S, Button K, Churchill R, Croudace T, Derrick C, Dixon P, Dowrick C, Fawsitt C, Fusco L, Gilbody S, Harmer C, Hobbs C, Hollingworth W, Jones V, Kendrick T, Kessler D, Khan N, Kounali D, Lanham P, Malpass A, Munafo M, Pervin J, Peters T, Riozzie D, Robinson J, Salaminios G, Sharp D, Thom H, Thomas L, Welton N, Wiles N, Woodhouse R, Lewis G.
    ; 2019 12 03. PubMed ID: 31869013
    [Abstract] [Full Text] [Related]

  • 9. Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT.
    Thomas SA, Drummond AE, Lincoln NB, Palmer RL, das Nair R, Latimer NR, Hackney GL, Mandefield L, Walters SJ, Hatton RD, Cooper CL, Chater TF, England TJ, Callaghan P, Coates E, Sutherland KE, Eshtan SJ, Topcu G.
    Health Technol Assess; 2019 Sep 03; 23(47):1-176. PubMed ID: 31524133
    [Abstract] [Full Text] [Related]

  • 10. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D, Burns A, Tallon D, Lewis G, MacNeill S, Round J, Hollingworth W, Chew-Graham C, Anderson I, Campbell J, Dickens C, Macleod U, Gilbody S, Davies S, Peters TJ, Wiles N.
    Health Technol Assess; 2018 Nov 03; 22(63):1-136. PubMed ID: 30468145
    [Abstract] [Full Text] [Related]

  • 11. Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial.
    Tallon D, Wiles N, Campbell J, Chew-Graham C, Dickens C, Macleod U, Peters TJ, Lewis G, Anderson IM, Gilbody S, Hollingworth W, Davies S, Kessler D.
    Trials; 2016 Feb 03; 17():66. PubMed ID: 26842107
    [Abstract] [Full Text] [Related]

  • 12. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
    Salaminios G, Duffy L, Ades A, Araya R, Button KS, Churchill R, Croudace T, Derrick C, Dixon P, Dowrick C, Gilbody S, Hollingworth W, Jones V, Kendrick T, Kessler D, Kounali D, Lanham P, Malpass A, Peters TJ, Riozzie D, Robinson J, Sharp D, Thomas L, Welton NJ, Wiles N, Lewis G.
    Trials; 2017 Oct 24; 18(1):496. PubMed ID: 29065916
    [Abstract] [Full Text] [Related]

  • 13. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT.
    Clare L, Kudlicka A, Oyebode JR, Jones RW, Bayer A, Leroi I, Kopelman M, James IA, Culverwell A, Pool J, Brand A, Henderson C, Hoare Z, Knapp M, Morgan-Trimmer S, Burns A, Corbett A, Whitaker R, Woods B.
    Health Technol Assess; 2019 Mar 24; 23(10):1-242. PubMed ID: 30879470
    [Abstract] [Full Text] [Related]

  • 14. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.
    Lewis G, Duffy L, Ades A, Amos R, Araya R, Brabyn S, Button KS, Churchill R, Derrick C, Dowrick C, Gilbody S, Fawsitt C, Hollingworth W, Jones V, Kendrick T, Kessler D, Kounali D, Khan N, Lanham P, Pervin J, Peters TJ, Riozzie D, Salaminios G, Thomas L, Welton NJ, Wiles N, Woodhouse R, Lewis G.
    Lancet Psychiatry; 2019 Nov 24; 6(11):903-914. PubMed ID: 31543474
    [Abstract] [Full Text] [Related]

  • 15. Novel Augmentation Strategies in Major Depression.
    Martiny K.
    Dan Med J; 2017 Apr 24; 64(4):. PubMed ID: 28385173
    [Abstract] [Full Text] [Related]

  • 16. Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol.
    Furukawa TA, Akechi T, Shimodera S, Yamada M, Miki K, Watanabe N, Inagaki M, Yonemoto N.
    Trials; 2011 May 11; 12():116. PubMed ID: 21569309
    [Abstract] [Full Text] [Related]

  • 17. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial.
    Bergh S, Selbæk G, Engedal K.
    BMJ; 2012 Mar 09; 344():e1566. PubMed ID: 22408266
    [Abstract] [Full Text] [Related]

  • 18. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
    Behnke K, Søgaard J, Martin S, Bäuml J, Ravindran AV, Agren H, Vester-Blokland ED.
    J Clin Psychopharmacol; 2003 Aug 09; 23(4):358-64. PubMed ID: 12920411
    [Abstract] [Full Text] [Related]

  • 19. Mirtazapine versus other antidepressive agents for depression.
    Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA.
    Cochrane Database Syst Rev; 2011 Dec 07; (12):CD006528. PubMed ID: 22161405
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.